Update: Report: Abbott prescription med unit could bring $54B

Yesterday's announcement of Abbott Laboratories' ($ABT) split into two companies has prompted speculation over whether the prescription-medicine spin-off could become a takeover target. Some analysts are saying that the company could fetch as much as $54 billion. Jeffrey Holford, a Jefferies Group analyst, names Merck ($MRK), Roche and Bayer as potential interested parties. News

Editor's Note: The headline for this story was updated and corrected to change the potential sum of a buyout of Abbott's prescription medicine business from $54 million to $54 billion.

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.

Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.